These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 17896925)

  • 1. Supramolecular devices for the high-throughput screening of drugs, nutrients and metabolites in postgenomic era (part 1).
    Bazylak G
    Comb Chem High Throughput Screen; 2007 Jun; 10(5):299-300. PubMed ID: 17896925
    [No Abstract]   [Full Text] [Related]  

  • 2. Modeling promiscuity based on in vitro safety pharmacology profiling data.
    Azzaoui K; Hamon J; Faller B; Whitebread S; Jacoby E; Bender A; Jenkins JL; Urban L
    ChemMedChem; 2007 Jun; 2(6):874-80. PubMed ID: 17492703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Supramolecular devices for the high-throughput screening of drugs, nutrients and metabolites in postgenomic era (part 3).
    Bazylak G
    Comb Chem High Throughput Screen; 2007 Aug; 10(7):493-4. PubMed ID: 17979633
    [No Abstract]   [Full Text] [Related]  

  • 4. Proposal for a harmonized descriptive analyte nomenclature for quantitative large-molecule bioanalysis.
    Heinrich J; Staack RF; Stubenrauch KG; Papadimitriou A
    Bioanalysis; 2015 Dec; 7(24):3057-62. PubMed ID: 26505951
    [No Abstract]   [Full Text] [Related]  

  • 5. Finding time for allosteric interactions.
    Wainer IW
    Nat Biotechnol; 2004 Nov; 22(11):1376-7. PubMed ID: 15529160
    [No Abstract]   [Full Text] [Related]  

  • 6. Structure-based drug design: strategies and challenges.
    Yang GF
    Curr Pharm Des; 2014; 20(5):685-6. PubMed ID: 23688085
    [No Abstract]   [Full Text] [Related]  

  • 7. "Intelligent" fingerprinting: simultaneous identification of drug metabolites and individuals by using antibody-functionalized nanoparticles.
    Leggett R; Lee-Smith EE; Jickells SM; Russell DA
    Angew Chem Int Ed Engl; 2007; 46(22):4100-3. PubMed ID: 17469083
    [No Abstract]   [Full Text] [Related]  

  • 8. Fluorescence-based liver microsomal assay for screening of pharmaceutical reactive metabolites using a glutathione conjugated 96-well plate.
    Ma X; Chan EC
    Bioconjug Chem; 2010 Jan; 21(1):46-55. PubMed ID: 19957910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-targeted screening of drugs.
    Cawley A
    Drug Test Anal; 2021 May; 13(5):892-893. PubMed ID: 33942542
    [No Abstract]   [Full Text] [Related]  

  • 10. Methyl-containing pharmaceuticals: Methylation in drug design.
    Sun S; Fu J
    Bioorg Med Chem Lett; 2018 Nov; 28(20):3283-3289. PubMed ID: 30243589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for content--the evolution of high throughput.
    Dove A
    Nat Biotechnol; 2003 Aug; 21(8):859-64. PubMed ID: 12894197
    [No Abstract]   [Full Text] [Related]  

  • 12. 'Metabolite-likeness' as a criterion in the design and selection of pharmaceutical drug libraries.
    Dobson PD; Patel Y; Kell DB
    Drug Discov Today; 2009 Jan; 14(1-2):31-40. PubMed ID: 19049901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functionally engineered nanosized particles in pharmaceutics: improved oral delivery of poorly water-soluble drugs.
    Ozeki T; Tagami T
    Curr Pharm Des; 2013; 19(35):6259-69. PubMed ID: 23470003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ligand efficiency indices as guideposts for drug discovery.
    Abad-Zapatero C; Metz JT
    Drug Discov Today; 2005 Apr; 10(7):464-9. PubMed ID: 15809192
    [No Abstract]   [Full Text] [Related]  

  • 15. Recommendations on the Development of a Bioanalytical Assay for 4β-Hydroxycholesterol, an Emerging Endogenous Biomarker of CYP3A Activity.
    Aubry AF; Dean B; Diczfalusy U; Goodenough A; Iffland A; McLeod J; Weng N; Yang Z
    AAPS J; 2016 Sep; 18(5):1056-1066. PubMed ID: 27350147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimizing metabolic activation during pharmaceutical lead optimization: progress, knowledge gaps and future directions.
    Kumar S; Kassahun K; Tschirret-Guth RA; Mitra K; Baillie TA
    Curr Opin Drug Discov Devel; 2008 Jan; 11(1):43-52. PubMed ID: 18175266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent examples of novel secondary metabolites.
    Brown AG
    Folia Microbiol (Praha); 1995; 40(1):31-42. PubMed ID: 8851465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Availability of plethora of bioanalytical assays for several commonly prescribed drugs - a problem of plenty: perspectives.
    Srinivas NR
    Biomed Chromatogr; 2016 May; 30(5):668-9. PubMed ID: 26892432
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacologically active drug metabolites: impact on drug discovery and pharmacotherapy.
    Obach RS
    Pharmacol Rev; 2013 Apr; 65(2):578-640. PubMed ID: 23406671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tiered approach revisited: introducing stage-appropriate or assay-appropriate scientific validation.
    Timmerman P
    Bioanalysis; 2014 Mar; 6(5):599-604. PubMed ID: 24620801
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.